RNAC Cartesian Therapeutics
- 28.260
- +3.690+15.02%
- 28.540
- +0.280+0.99%
Cartesian Therapeutics News
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Cuts Target Price to $40
Mizuho Securities analyst Uy Ear maintains $Cartesian Therapeutics(RNAC.US)$ with a buy rating, and adjusts the target price from $90 to $40.According to TipRanks data, the analyst has a success rate
Cartesian Therapeutics Price Target Announced at $40.00/Share by Mizuho
Cartesian Therapeutics Price Target Announced at $40.00/Share by Mizuho
Cartesian Therapeutics Inc.: Mizuho sets purchase rating and target share price of $40 for the first time
Cartesian Therapeutics Inc.: Mizuho sets purchase rating and target share price of $40 for the first time
Express News | Cartesian Therapeutics Inc : Mizuho Initiates With Buy Rating and $40 Price Target
Buy Rating Affirmed for Cartesian Therapeutics Amidst Promising Clinical Advancements and Strategic Positioning
H.C. Wainwright Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $54
H.C. Wainwright analyst Mitchell Kapoor maintains $Cartesian Therapeutics(RNAC.US)$ with a buy rating, and maintains the target price at $54.According to TipRanks data, the analyst has a success rate
Cartesian Stock Climbs 8% on FDA Regenerative Therapy Designation
Cartesian Therapeutics shares rose 8.3% due to the US Food and Drug Administration's “rmat” label for treating autoimmune diseases
Cartesian Therapeutics shares rose 8.3% due to the US Food and Drug Administration's “rmat” label for treating autoimmune diseases
Express News | Cartesian Therapeutics Shares up 8.3% on Fda's 'rmat' Tag for Autoimmune Disorder Treatment
Express News | Cartesian- on Track to Post Topline Data From Phase 2B Randomized, Placebo-Controlled Trial of Descartes-08 in Patients With Mg in Mid-2024
Express News | Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GAITHERSBURG, Md., May 13, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today
Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ...
Buy Rating Affirmed for Cartesian Therapeutics on Strong Clinical Progress and Strategic Expansion
HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $54 Price Target
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $54 price target.
Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham
Cartesian Therapeutics Price Target Maintained With a $42.00/Share by Needham
Needham: Reiterates Cartesian Therapeutics (RNAC.US) rating and adjusted from buy to buy rating, target price is $42.00.
Needham: Reiterates Cartesian Therapeutics (RNAC.US) rating and adjusted from buy to buy rating, target price is $42.00.
Needham Reiterates Buy on Cartesian Therapeutics, Maintains $42 Price Target
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $42 price target.
Cartesian Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 82.85% Needham → $42 Reiterates Buy → Buy 04/23/2024 135.09% HC Wainwright & Co. $2 → $54 Maint
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)
Analysis
Price Target
No Data
